TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer
文献类型：期刊论文
| 作者 | Liu, Xiaoyue3,4; Zhou, Tianhao2; Wang, Yongmei3,4; Pei, Min3,4; Wang, Guifeng3,4 ; Chu, Wendi3,4; Wang, Qi3,4; Du, Shaoqian2; Wang, Hongxia2; Wang, Chunhe1,3,4
|
| 刊名 | ONCOTARGETS AND THERAPY
 |
| 出版日期 | 2022 |
| 卷号 | 15页码:509-520 |
| 关键词 | TROP2 breast cancer triple-negative breast cancer antibody-drug conjugate biomarker |
| ISSN号 | 1178-6930 |
| DOI | 10.2147/OTT.S354048 |
| 通讯作者 | Wang, Hongxia(whx365@126.com) ; Wang, Chunhe(wangc@simm.ac.cn) |
| 英文摘要 | Purpose: Trophoblast cell surface antigen 2 (TROP2) has emerged as a promising target of antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC), as well as other breast cancers (BCs). This study aims to investigate the biomarker value of TROP2 for patient-tailoring and prognostic for BC patients, including TNBC. Methods: The levels of TROP2 expression in 404 Chinese BC tissues on tissue microarrays (TMAs) were quantified by immunohistochemistry and their correlations to the clinicopathological factors and the overall survival rate were analyzed. Also, BC cell lines and patient-derived organoids (PDOs) with different TROP2 expression levels were employed to investigate the correlation between TROP2 expression levels and the therapeutic responses to DS001, a TROP2-directed ADC molecule with stable linker and potent payload. Results: TROP2 overexpression was identified in significantly more (P = 0.046) tumor tissues (41.08%, 99/241) than normal adjacent tissues (31.29%, 51/163) from Chinese BC patients, and in significantly more (P = 0.024) TNBC patients (59.38%, 19/32) than in other BC types (38.28%, 80/209). BC cell line with the lowest TROP2 expression level failed to respond to DS001 treatment. The levels of TROP2 expression were determined to be significantly correlated with the potencies of DS001 treatment, but not with the overall survival rates of the patients. Conclusion: Our results demonstrated that TROP2 could serve as a patient-tailoring and predictive biomarker for ADC therapeutics but not as a general prognostic biomarker to predicate patient survival. |
| WOS关键词 | SACITUZUMAB GOVITECAN IMMU-132 |
| WOS研究方向 | Biotechnology & Applied Microbiology ; Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000829586300008 |
| 出版者 | DOVE MEDICAL PRESS LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/302007]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, Hongxia; Wang, Chunhe |
| 作者单位 | 1.Dartsbio Pharmaceut, Res & Dev Ctr, Zhongshan, Peoples R China 2.Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China 3.Univ Chinese Acad Sci, Beijing, Peoples R China 4.Chinese Acad Sci, Biotherapeut Discovery Res Ctr, Shanghai Inst Mat Med, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liu, Xiaoyue,Zhou, Tianhao,Wang, Yongmei,et al. TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer[J]. ONCOTARGETS AND THERAPY,2022,15:509-520. |
| APA | Liu, Xiaoyue.,Zhou, Tianhao.,Wang, Yongmei.,Pei, Min.,Wang, Guifeng.,...&Wang, Chunhe.(2022).TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer.ONCOTARGETS AND THERAPY,15,509-520. |
| MLA | Liu, Xiaoyue,et al."TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer".ONCOTARGETS AND THERAPY 15(2022):509-520. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。